Several systemic treatments have been shown to increase survival for patients with metastatic castration-resistant prostate cancer. This study sought to characterize variation in use of the six “focus drugs” (...
Authors: Megan E. V. Caram, Jason P. Estes, Jennifer J. Griggs, Paul Lin and Bhramar Mukherjee
Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicente...
Authors: Dae-Won Lee, Kyung-Hun Lee, Hee-Jun Kim, Tae-Yong Kim, Jin-Soo Kim, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Seock-Ah Im and Tae-You Kim
Esophageal sarcomatoid carcinoma (ESC) is a rare disease with a mixture of both carcinomatous and sarcomatous components in the tumor. Its genetic background and mechanisms of oncogenesis remain largely unknown.
Authors: Hongyang Lu, Shifeng Yang, Huineng Zhu, Xiaoling Tong, Fajun Xie, Jing Qin, Na Han, Xue Wu, Yun Fan, Yang W. Shao and Weimin Mao
Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can ...
Authors: Surabhi Ranjan, Martha Quezado, Nancy Garren, Lisa Boris, Christine Siegel, Osorio Lopes Abath Neto, Brett J. Theeler, Deric M. Park, Edjah Nduom, Kareem A. Zaghloul, Mark R. Gilbert and Jing Wu
The immune system has a known role in the aetiology, progression and final treatment outcome of oral squamous cell cancers. The aim of this study was to evaluate the influence of radical surgery and radiothera...
Authors: Tadej Dovšak, Alojz Ihan, Vojko Didanovič, Andrej Kansky, Miha Verdenik and Nataša Ihan Hren
There is no consensus regarding the optimal time to initiate adjuvant chemotherapy after surgery for stage III colon cancer, and the relevant postoperative complications that cause delays in adjuvant chemother...
Authors: Peng Gao, Xuan-zhang Huang, Yong-xi Song, Jing-xu Sun, Xiao-wan Chen, Yu Sun, Yu-meng Jiang and Zhen-ning Wang
Cancer stem cells (CSCs) are believed to promote the malignant transformation of breast cancer via multiple signaling pathways, including the Wnt/β-catenin pathway. Leucine-rich repeat-containing G protein-cou...
Authors: Ming-Feng Hou, Po-Ming Chen and Pei-Yi Chu
Gamma Knife radiosurgery (GKRS) is increasingly applied in patients with multiple brain metastases and is expected to have less adverse effects in cognitive functioning than whole brain radiation therapy (WBRT...
Authors: Wietske C. M. Schimmel, Eline Verhaak, Patrick E. J. Hanssens, Karin Gehring and Margriet M. Sitskoorn
Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs...
Authors: Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne and Isabelle Durand-Zaleski
Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.
Authors: Yu Qiao, Jihong Yang, Lili Liu, Yixin Zeng, Jie Ma, Jing Jia, Li Zhang, Xiaoguang Li, Peihong Wu, Wenchao Wang, Dongge Liu, Huan Chen, Yunbo Zhao, Huan Xi and Yao Wang
Survival advantage following trans-arterial chemoembolization (TACE) is variable in patients with hepatocellular carcinoma (HCC). We combined pre-TACE radiologic features to derive a novel prognostic signature...
Authors: David J. Pinato, Madhava Pai, Isabella Reccia, Markand Patel, Alexandros Giakoustidis, Georgios Karamanakos, Azelea Rushd, Shiraz Jamshaid, Alberto Oldani, Glenda Grossi, Mario Pirisi, Paul Tait and Rohini Sharma
To evaluate the prevalence of metastatic tumors involving the myocardium and study their presentation in order to increase awareness to their existence.
Authors: Ivana Burazor, Sarit Aviel-Ronen, Massimo Imazio, Orly Goitein, Marina Perelman, Natalia Shelestovich, Ninoslav Radovanovic, Vladimir Kanjuh, Iris Barshack and Yehuda Adler
Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utilit...
Authors: Duneesha de Fonseka, David T. Arnold, Louise Stadon, Anna Morley, Emma Keenan, Michael Darby, Lynne Armstrong, Paul Virgo and Nick A. Maskell
The aim of the present trial is to investigate a new option of skin protection in order to reduce the rate of grade ≥ 2 skin toxicity in patients receiving radiotherapy alone or radiochemotherapy for locally a...
Authors: Carlos Narvaez, Claudia Doemer, Christian Idel, Cornelia Setter, Denise Olbrich, Zaza Ujmajuridze, Jesper Hansen Carl and Dirk Rades
RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit ...
Authors: Lin Yang, Anna Alyasova, Dingwei Ye, Antonia Ridolfi, Luca Dezzani and Robert J. Motzer
Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only sec...
Authors: Marina Pulido, Guilhem Roubaud, Anne-Laure Cazeau, Hakim Mahammedi, Lionel Vedrine, Florence Joly, Loic Mourey, Christian Pfister, Alejandro Goberna, Barbara Lortal, Carine Bellera, Philippe Pourquier and Nadine Houédé
To evaluate survival data and local tumor control after transarterial chemoembolization in two groups with different embolization protocols for the treatment of HCC patients.
Authors: Tatjana Gruber-Rouh, Cornelia Schmitt, Nagy N. N. Naguib, N. A. Nour-Eldin, Katrin Eichler, Martin Beeres and Thomas J. Vogl
Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combina...
Authors: Tsutomu Namikawa, Hiromichi Maeda, Hiroyuki Kitagawa, Koji Oba, Akihito Tsuji, Takaki Yoshikawa, Michiya Kobayashi and Kazuhiro Hanazaki
Mutations in BRCA1 and BRCA2 (BRCA1/2) genes are associated with an increased risk of breast and ovarian cancers in women. The cancer characteristics of men with BRCA1/2 mutations are less well studied. This stud...
Authors: Mohammed Ibrahim, Siddhartha Yadav, Foluso Ogunleye and Dana Zakalik
Patients with advanced lung cancer (LC) or malignant pleural mesothelioma (MPM) exhibit limitation of exercise capacities and alteration of quality of life (QoL) induced by cancer and its treatment. Few studie...
Authors: Cecile Olivier, Jean-Marie Grosbois, Alexis B. Cortot, Sophie Peres, Christophe Heron, Julie Delourme, Marianne Gierczynski, Anne Hoorelbeke, Arnaud Scherpereel and Olivier Le Rouzic
Serious neurological adverse events (NAE) have occurred during treatment with high-dose thiotepa regimens of children with high-risk solid tumours. The objective was to assess the incidence of NAE related to h...
The clinical utility and prognostic impact of presumed primary breast or ovarian cancer among patients with an unfavorable subset of cancer of unknown primary site (CUP) remains unclear. We aimed to evaluate t...
Authors: Makoto Kodaira, Kan Yonemori, Tatsunori Shimoi, Akihiko Yoshida, Masayuki Yoshida, Atsuko Kitano, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yuichi Takiguchi, Yasuhiro Fujiwara and Kenji Tamura
Brain metastases from gastric cancer are difficult to treat and their prognosis is poor. Despite various possible treatments, the survival rate of such patients is still unsatisfactory; therefore, new treatmen...
Authors: Min-joo Ahn, Kanghan Lee, Kyung Hwa Lee, Jin Woong Kim, In-Young Kim and Woo Kyun Bae
The optimal first-line chemotherapy for ovarian carcinosarcoma has not yet been determined. We therefore sought to determine the progression-free survival (PFS) and overall survival (OS) for patients with ovar...
Authors: Melissa Brackmann, Marina Stasenko, Shitanshu Uppal, Jake Erba, R. Kevin Reynolds and Karen McLean
Metastases to the thyroid gland are more frequent than previously thought, although most of them are occult or not clinically relevant. Overall, only 42 cases of metastases to thyroid from breast cancer have b...
Authors: Matilde Pensabene, Brigida Stanzione, Ivana Cerillo, Giuseppe Ciancia, Immacolata Cozzolino, Raffaella Ruocco, Caterina Condello, Giuseppe Di Lorenzo, Mario Giuliano, Valeria Forestieri, Grazia Arpino, Sabino De Placido and Rossella Lauria
Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies. However, its patterns of response has not yet been full...
Due to the ageing population and improving diagnostics and treatments, the number of cancer patients and cancer survivors is increasing. Policymakers, patients and professionals advocate a transfer of (part of...
Authors: I. A. A. Perfors, C. W. Helsper, E. A. Noteboom, E. van der Wall, N. J. de Wit and A. M. May
Hodgkin’s lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) are the two most common tumors expressing CD30. Internationally, a clinical study that is being conducted involving adults with recurrent or re...
Authors: Masahiro Sekimizu, Akihiro Iguchi, Tetsuya Mori, Yuhki Koga, Akiko Kada, Akiko M. Saito and Keizo Horibe
Ramucirumab has recently proved to be effective for advanced or recurrent gastric cancer (AGC). Ascites and peritoneal metastasis are among the most common complications of AGC. However, there are few data on ...
Neoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have re...
To evaluate the prognostic significance of pretreatment quality of life for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Authors: Shan-Shan Guo, Wen Hu, Qiu-Yan Chen, Jian-Mei Li, Shi-Heng Zhu, Yan He, Jia-Wen Li, Le Xia, Lu Ji, Cui-Ying Lin, Li-Ting Liu, Lin-Quan Tang, Ling Guo, Hao-Yuan Mo, Chong Zhao, Xiang Guo…
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is l...
Authors: Edurne Arriola, Ramón García Gómez, Pilar Diz, Margarita Majem, Maite Martínez Aguillo, Javier Valdivia, Alfredo Paredes, José Miguel Sánchez-Torres, Sergio Peralta Muñoz, Isidoro Barneto, Vanesa Gutierrez, Jesús Manuel Andrade Santiago, Francisco Aparisi, Dolores Isla, Santiago Ponce, David Vicente Baz…
Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expre...
Authors: Shang-Yu Chou, Shao-Lun Yen, Chao-Cheng Huang and Eng-Yen Huang
The prognosis of hepatocellular carcinoma with portal vein tumor thrombus remains extremely poor. This pilot study aimed to evaluate the technical feasibility, effectiveness and safety of transcatheter chemoem...
Authors: Biao Yang, Chun-Lin Li, Wen-hao Guo, Tian-qiang Qin, He Jiao, Ze-jun Fei, Xuan Zhou, Lin-jia Duan and Zheng-yin Liao
Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for
Authors: Francesca Battaglin, Marta Schirripa, Federica Buggin, Filippo Pietrantonio, Federica Morano, Giorgia Boscolo, Giuseppe Tonini, Eufemia Stefania Lutrino, Jessica Lucchetti, Lisa Salvatore, Alessandro Passardi, Chiara Cremolini, Ermenegildo Arnoldi, Mario Scartozzi, Nicoletta Pella, Luca Boni…
Herein, we report a complete response after whole brain radiotherapy (WBRT) and concomitant T-DM1 in a patient with HER2-positive metastatic breast cancer (MBC) and extensive brain and leptomeningeal involvement.
Authors: Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, Silvia Schifano, Giampiero Mastroeni, Anna Santacaterina and Vincenzo Adamo
Immune checkpoint blockade is developed as standard treatment for non-small cell lung cancer. However immune-related adverse events (irAE) have still unknown complications. Here, we report a patient with lung ...
Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class of agents. The current opinion is th...
Authors: Arie J. Verschoor, Fabiënne A. R. M. Warmerdam, Tjalling Bosse, Judith V. M. G. Bovée and Hans Gelderblom
To determine the effect of Yttrium-90 (Y90) radioembolization on health-related quality of life (HRQOL) and its effect on overall survival advanced, unresectable infiltrative hepatocellular carcinoma (HCC) pat...
Authors: Minzhi Xing, Nima Kokabi, Juan C. Camacho and Hyun S. Kim
Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcit...
Authors: Alexander R. Siebenhüner, Heike Seifert, Helga Bachmann, Burkhardt Seifert, Thomas Winder, Jonas Feilchenfeldt, Stefan Breitenstein, Pierre-Alain Clavien, Roger Stupp, Alexander Knuth, Bernhard Pestalozzi and Panagiotis Samaras
Oxaliplatin + S-1 is a recognized treatment regimen in Japan, but there are no Japanese clinical data on an oxaliplatin dose of 130 mg/m2. The current research involves a single-arm, prospective, phase II clinica...
Authors: Hiroshi Saeki, Yasunori Emi, Eiji Oki, Shoji Tokunaga, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Eishi Baba and Yoshihiko Maehara
Systemic treatment for advanced cancer offers uncertain and sometimes little benefit while the burden can be high. Hence, treatment decisions require Shared Decision Making (SDM). The CHOICE trial examines the...
Authors: I. Henselmans, E. M. A. Smets, J. C. J. M. de Haes, M. G. W. Dijkgraaf, F. Y. de Vos and H. W. M. van Laarhoven
The topic of trastuzumab therapy without chemotherapy in early breast cancer (EBC) has been repeatedly discussed at international consensus meetings, but is compromised by the lack of solid evidence from clini...
Authors: Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Nicolas Schleif, Ursula Cirrincione, Axel Hinke and Gabriele Feisel-Schwickardi
The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The RS ri...
Authors: Gulisa Turashvili, Edi Brogi, Monica Morrow, Maura Dickler, Larry Norton, Clifford Hudis and Hannah Y. Wen
Glioblastoma relapses in the vast majority of cases within 1 year. Maximum safe resection of the recurrent glioblastoma can be offered in some cases. Re-irradiation has been established for the treatment of re...
Authors: Christoph Straube, Hagen Scherb, Jens Gempt, Jan Kirschke, Claus Zimmer, Friederike Schmidt-Graf, Bernhard Meyer and Stephanie E. Combs
To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real...
LUX-Lung 3 showed afatinib improved progression-free survival (PFS) compared with cisplatin plus pemetrexed in patients with epidermal growth factor receptor (EGFR) mutations. In this study, chemotherapy efficacy...
Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, ther...
Authors: Feifei Sun, Jia Zhu, Suying Lu, Zijun Zhen, Juan Wang, Junting Huang, Zonghui Ding, Musheng Zeng and Xiaofei Sun
Historical data indicate that surgical resection may benefit select patients with metastatic gastric and gastroesophageal junction cancer. However, randomized clinical trials are lacking. The current RENAISSAN...
Authors: Salah-Eddin Al-Batran, Thorsten O. Goetze, Daniel W. Mueller, Arndt Vogel, Michael Winkler, Sylvie Lorenzen, Alexander Novotny, Claudia Pauligk, Nils Homann, Thomas Jungbluth, Christoph Reissfelder, Karel Caca, Steffen Retter, Eva Horndasch, Julia Gumpp, Claus Bolling…
This phase II bridging study assessed the safety and efficacy of nab-paclitaxel/gemcitabine (Metastatic Pancreatic Adenocarcinoma Clinical Trial [MPACT] regimen) in Chinese patients with metastatic pancreatic can...
Authors: Ruihua Xu, Xianjun Yu, Jihui Hao, Liwei Wang, Hongming Pan, Guohong Han, Jianming Xu, Yanqiao Zhang, Shujun Yang, Jia Chen, Jieer Ying, Guanghai Dai, Mingyu Li, Damir Begic, Brian Lu and Lin Shen
